[1]
Duan, Y-T.; Sangani, C.B.; Liu, W.; Soni, K.V.; Yao, Y. New promises to cure cancer and other genetic diseases/disorders: Epi-drugs through epigenetics. Curr. Top. Med. Chem., 2019, 19(12), 972-994.
[2]
Bai, Y.; Ahmad, D.; Wang, T.; Cui, G.; Li, W. Research advances in the use of histone deacetylase inhibitors for epigenetic targeting of cancer. Curr. Top. Med. Chem., 2019, 19(12), 995-1004.
[3]
Peng, X.; Liao, G.; Sun, P.; Yu, Z.; Chen, J. An overview of HDAC inhibitors and their synthetic routes. Curr. Top. Med. Chem., 2019, 19(12), 1005-1040.
[4]
Lu, H.; Bai, L.; Zhou, Y.; Lu, Y.; Jiang, Z.; Shi, J. Recent study of dual HDAC/PARP inhibitor for the treatment of tumor. Curr. Top. Med. Chem., 2019, 19(12), 1041-1050.
[5]
Wang, T.; Xu, Z.; Lu, Y.; Qi, B.; Bai, L.; Liu, W.; Zhang, C.; Jiang, Z. Recent progress on discovery of Sirt2 inhibitors for the treatment of various cancers. Curr. Top. Med. Chem., 2019, 19(12), 1051-1058.
[6]
Yin, L.; Xue, Y.; Shang, Q.; Zhu, H.; Liu, M.; Liu, Y.; Hu, Q. Pharmaceutical inhibition of neddylation as promising treatments for various cancers. Curr. Top. Med. Chem., 2019, 19(12), 1059-1069.
